Sitryx Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $39M
Overview
A biotech targeting immunometabolism to develop novel therapies for autoimmune diseases, inflammation, and cancer.
ImmunologyOncologyMetabolic
Technology Platform
A discovery platform focused on identifying and drugging key metabolic pathways in immune cells to treat inflammatory diseases and cancer.
Funding History
1Total raised:$39M
Series A$39M
Opportunities
Potential to create first-in-class, oral therapies for autoimmune diseases where current injectable biologics dominate.
Risk Factors
High biological complexity and risk of unforeseen on-target toxicities when systemically modulating core metabolic pathways.
Competitive Landscape
A frontrunner in the nascent but promising immunometabolism field, competing to translate complex biology into viable drugs.